VA Federal Supply Schedule Contract Terms May Extend to 20 Years For pharmaceutical manufacturers with VA Federal Supply Schedule (FSS) agreements, the Department of Veterans Affairs (VA) recently announced a structural change that could affect long-term planning,...
CMS Delays New Q1 2026 ASP Reporting Requirements CMS has announced that the new ASP reporting requirements tied to bona fide service fee certifications and reasonable assumptions will be waived for the first sales quarter of 2026 due to implementation delays. As a...
What the 12-Digit NDC Means for Government Pricing, Rebates, and Reporting The FDA recently finalized a rule transitioning National Drug Codes (NDCs) from the current 10 and 11 digit formats to a standardized 12-digit NDC structure (6-4-2). Implementation begins March...
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30 Under the 2026 CMS Final Rule, pharmaceutical manufacturers face a new compliance requirement: beginning with Q1 2026 ASP reporting, manufacturers must submit a Reasonable Assumptions Form...
Congress Just Drew a Line on PBM Compensation Recently, President Trump signed the Consolidated Appropriations Act of 2026, avoiding a government shutdown and setting federal funding for the year. Included inside the bill is a major policy change that will reshape how...
Nevada Essential Drug List Reporting Requirements for Pharmaceutical Manufacturers Nevada’s drug price transparency law includes annual reporting obligations for pharmaceutical manufacturers whose products appear on the Nevada Essential Drug List. Inclusion on the...
Medicare Part D Inflation Rebates: January 9 Deadline Approaching As the January 9 deadline for Medicare Part D Inflation Rebates approaches, drug manufacturers are entering one of the most consequential compliance checkpoints introduced under the Inflation Reduction...
2026 CMS Final Rule: Expanded ASP Reporting and Verification Requirements for Manufacturers On November 5, 2025, CMS released the Calendar Year 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare...
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing ShiftsThe Trump administration’s latest policy signals could mark a significant change for the pharmaceutical sector - combining the threat of sweeping tariffs on branded drugs with the...